ProKidney Corp/$PROK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ProKidney Corp
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Ticker
$PROK
Sector
Primary listing
Employees
231
Headquarters
Website
ProKidney Corp Metrics
BasicAdvanced
$373m
-
-$0.53
1.75
-
Price and volume
Market cap
$373m
Beta
1.75
52-week high
$7.13
52-week low
$0.55
Average daily volume
931k
Financial strength
Current ratio
9.059
Quick ratio
8.715
Long term debt to equity
1.017
Total debt to equity
1.438
Interest coverage (TTM)
-8,871.16%
Profitability
EBITDA (TTM)
-161.919
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-8,131.50%
Operating margin (TTM)
-18,959.73%
Effective tax rate (TTM)
0.11%
Management effectiveness
Return on assets (TTM)
-30.15%
Return on equity (TTM)
-49.37%
Valuation
Price to revenue (TTM)
281.865
Price to book
-0.25
Price to tangible book (TTM)
-0.25
Price to free cash flow (TTM)
-1.67
Free cash flow yield (TTM)
-59.88%
Free cash flow per share (TTM)
-1.09
Growth
Revenue change (TTM)
190.52%
Earnings per share change (TTM)
-12.20%
3-year earnings per share growth (CAGR)
-28.44%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs